Predictors of use of direct oral anticoagulants in patients with venous thromboembolism

Current guidelines recommend the use of direct oral anticoagulants (DOACs) for patients with venous thromboembolism (VTE). However little is known about the use of DOACs in daily practice. We used the RIETE registry to identify predictors of use of DOACs for initial and/or long-term therapy of VTE b...

Full description

Bibliographic Details
Authors: Lorenzo, Alicia, Beroiz Groh, Patricia|||0009-0006-5466-4082, Ortiz, Salvador, Del Toro, Jorge|||0000-0003-1791-9550, Mazzolai, Lucia, Bura-Riviere, Alessandra, Visonà, Adriana, Verhamme, Peter|||0000-0001-8698-2858, Di Micco, Pierpaolo, Camporese, Giuseppe, Sancho Bueso, Teresa, Monreal Bosch, Manuel|||0000-0002-0494-0767
Format: article
Publication Date:2022
Country:España
Institution:Universitat Autònoma de Barcelona
Repository:Dipòsit Digital de Documents de la UAB
Language:English
OAI Identifier:oai:ddd.uab.cat:281768
Online Access:https://ddd.uab.cat/record/281768
https://dx.doi.org/urn:doi:10.3389/fmed.2022.991376
Access Level:Open access
Keyword:Anticoagulant therapy
Different countries
Direct oral anticoagulants
Predictors
RIETE
Venous thromboembolism
Description
Summary:Current guidelines recommend the use of direct oral anticoagulants (DOACs) for patients with venous thromboembolism (VTE). However little is known about the use of DOACs in daily practice. We used the RIETE registry to identify predictors of use of DOACs for initial and/or long-term therapy of VTE based on patient-related factors, institution-related factors or over time. Among 41,678 patients from March 2013 to September 2021, 12,286 (29%) used DOACs: for initial therapy 6,456; for long-term therapy 12,046. On multivariable analysis, independent predictors were: age < 65 years (odds ratio [OR]: 1.30; 95% CI: 1.23-1.38), body weight <50 kg (OR: 0.54; 95% CI: 0.45-0.65) or.

Similar Items